Viviane Hess

2.0k total citations
52 papers, 1.4k citations indexed

About

Viviane Hess is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Viviane Hess has authored 52 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 18 papers in Surgery. Recurrent topics in Viviane Hess's work include Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Viviane Hess is often cited by papers focused on Gastric Cancer Management and Outcomes (12 papers), Esophageal Cancer Research and Treatment (11 papers) and Colorectal Cancer Treatments and Studies (8 papers). Viviane Hess collaborates with scholars based in Switzerland, Germany and Austria. Viviane Hess's co-authors include Thomas Ruhstaller, Richard Herrmann, Markus Borner, Piercarlo Saletti, Roger von Moos, Dieter Koeberle, G. Bodoky, Daniel Dietrich, Martin Gore and Walter Mingrone and has published in prestigious journals such as Journal of Clinical Oncology, The Lancet Oncology and British Journal of Cancer.

In The Last Decade

Viviane Hess

51 papers receiving 1.4k citations

Peers

Countries citing papers authored by Viviane Hess

Since Specialization

Citations

This map shows the geographic impact of Viviane Hess's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Viviane Hess with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Viviane Hess more than expected).

Fields of papers citing papers by Viviane Hess

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Viviane Hess. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Viviane Hess. The network helps show where Viviane Hess may publish in the future.

Co-authorship network of co-authors of Viviane Hess

This figure shows the co-authorship network connecting the top 25 collaborators of Viviane Hess. A scholar is included among the top collaborators of Viviane Hess based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Viviane Hess. Viviane Hess is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Hepatic Artery Infusion Chemotherapy for Primary and Secondary Malignancies of the Liver: State of the Art and Current High-Level Evidence 2024 ·Pharmacology ·Christoph Kuemmerli, Viviane Hess, Philipp Dutkowski, (unknown), Ulf Kessler, (unknown), Adrian T. Billeter, Beat P. Müller‐Stich, Otto Kollmar, Philip C. Müller	2
2	Group-based body psychotherapy improves appreciation of body awareness in post-treatment cancer patients: A non-randomized clinical trial 2023 ·Frontiers in Psychology ·(unknown), Cornelia Meffert, Viviane Hess, Christoph Rochlitz, Miklos Pless, Sabina Hunziker, (unknown), Ulfried Geuter, Gunther Meinlschmidt, Rainer Schaefert	2
3	Patterns of care for relapsed oesophageal cancer after initial curative trimodality therapy: Long-term follow-up of the SAKK 75/08 trial 2022 ·European Journal of Cancer ·Cédric Panje, Stefanie Hayoz, Wolfgang Eisterer, Viviane Hess, Peter Thuss‐Patience, (unknown), (unknown), Dorothea Wagner, Michael Girschikofsky, E.I. Eboulet, M. Stahl, Thomas Ruhstaller	2
4	https://researchopenworld.com/usability-testing-of-the-online-stress-management-intervention-stream-for-cancer-patients-results-and-implementations/# 2019 ·(unknown), (unknown), (unknown), Jens Gaab, Corinne Urech, Thomas Berger, Viviane Hess, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
5	Individually tailored whole-body vibration training to reduce symptoms of chemotherapy-induced peripheral neuropathy: study protocol of a randomised controlled trial—VANISH 2019 ·BMJ Open ·Fiona Streckmann, Viviane Hess, Wilhelm Bloch, Bernhard F. Décard, Ramona Ritzmann, Helmar C. Lehmann, Maryam Balke, (unknown), (unknown), Thomas Elter, Lukas Zahner, Lars Donath, Ralf Roth, Oliver Faude	2
6	A clinical trial of group-based body psychotherapy to improve bodily disturbances in post-treatment cancer patients in combination with randomized controlled smartphone-triggered bodily interventions (KPTK): study protocol 2019 ·BMC Psychology ·(unknown), Cornelia Meffert, Viviane Hess, Christoph Rochlitz, Miklos Pless, Sabina Hunziker, (unknown), Ulfried Geuter, Gunther Meinlschmidt, Rainer Schaefert	2
7	Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial. 2017 ·Journal of Clinical Oncology ·Thomas Ruhstaller, Peter Thuss‐Patience, Stefanie Hayoz, (unknown), Jorge Riera‐Knorrenschild, Annelies Schnider, Ludwig Plaßwilm, Wilfried Budach, Wolfgang Eisterer, Hanne Hawle, C. Mariette, Viviane Hess, Walter Mingrone, Dorothea Wagner, Michael Girschikofsky, (unknown), Michael Bitzer, Laurent Bedenne, Peter Brauchli, M. Stahl	4
8	Incidence and predictors of Bone Metastases (BM) and Skeletal-Related Events (SREs) in Small Cell Lung Cancer (SCLC): A Swiss patient cohort 2016 ·Journal of Cancer ·Katrin Conen, (unknown), Viviane Hess, Alfred Zippelius, Sacha I. Rothschild	19
9	Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06) 2015 ·Annals of Oncology ·Dieter Koeberle, Daniel Betticher, Roger von Moos, D. Dietrich, Peter Brauchli, (unknown), (unknown), Sun Young Rha, Markus Borner, Sandro Anchisi, Peter Moosmann, Attila Kollár, Piercarlo Saletti, A. Roth, M. Frueh, (unknown), Răzvan Popescu, (unknown), Viviane Hess, Richard Herrmann	92
10	Second-Line Therapy of Small-Cell Lung Cancer: Topotecan Compared to a Combination Treatment with Adriamycin, Cyclophosphamide And Vincristine (ACO) - a Single Center Experience 2015 ·Journal of Cancer ·(unknown), Viviane Hess, Alfred Zippelius, Sacha I. Rothschild	21
11	Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study 2014 ·BMC Cancer ·Benjamin Kasenda, (unknown), Dieter Koeberle, Bernhard C. Pestalozzi, Markus Borner, Richard Herrmann, Lorenz Jost, Andreas Lohri, Viviane Hess	37
12	Combining gemcitabine, oxaliplatin and capecitabine (GEMOXEL) for patients with advanced pancreatic carcinoma (APC): a phase I/II trial 2010 ·Annals of Oncology ·Viviane Hess, (unknown), Silke Potthast, (unknown), Sun Young Rha, Lukas Werner Widmer, (unknown), Andreas Lohri, L.M. Jost, (unknown), Bernhard C. Pestalozzi, Richard Herrmann	18
13	Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation? 2009 ·Supportive Care in Cancer ·Karin Ribi, Dieter Koeberle, Jan C. Schuller, Hanspeter Honegger, Arnaud Roth, Viviane Hess, Peter Moosmann, Roger von Moos, Markus Borner, Norbert Lombriser, Bernhard C. Pestalozzi, Thomas Ruhstaller	18
14	Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK 2008 ·Annals of Oncology ·Markus Borner, Dieter Koeberle, Roger von Moos, Piercarlo Saletti, Daniel Rauch, Viviane Hess, Andreas Trojan, Daniel Helbling, Bernhard C. Pestalozzi, Clemens B. Caspar, Thomas Ruhstaller, A. Roth, Андреас Каппелер, Damien Dietrich, Doris Lanz, Walter Mingrone	108
15	CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial 2008 ·The Lancet Oncology ·Viviane Hess, Bengt Glimelius, (unknown), Daniel Dietrich, G. Bodoky, Thomas Ruhstaller, Emilio Bajetta, Piercarlo Saletti, Arié Figer, Werner Scheithauer, Richard Herrmann	178
16	Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer 2008 ·British Journal of Cancer ·Dieter Koeberle, (unknown), Roger von Moos, Sun Young Rha, Viviane Hess, (unknown), Thomas Ruhstaller, L. Terraciano, (unknown), (unknown), (unknown), M. Toepfer	66
17	Interleukin-2-Based Biochemotherapy for Patients with Stage IV Melanoma: Long-Term Survivors Outside a Clinical Trial Setting 2007 ·Oncology ·Viviane Hess, Richard Herrmann, Hendrik Veelken, Michael Schwabe	6
18	Efficacy and Tolerability of Capecitabine with Weekly Paclitaxel for Patients with Metastatic Breast Cancer: A Phase II Report of the SAKK 2006 ·Oncology ·(unknown), Christoph Rochlitz, Walter Mingrone, Bernhard C. Pestalozzi, Daniel Rauch, Pierluigi Ballabeni, Doris Lanz, Viviane Hess, Stefan Aebi	8
19	INFECTION WITH HUMAN HERPESVIRUS 8 AND TRANSPLANT-ASSOCIATED GAMMOPATHY 2004 ·Transplantation ·Nicolas Regamey, Viviane Hess, Jakob Passweg, Christoph Hess, Jürg Steiger, Peter Erb, Gieri Cathomas, Michael Tamm	13
20	Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma 2003 ·Annals of Oncology ·Viviane Hess, Mark Verrill, (unknown), Matthew Vaughan, Mark Allen, Martin Gore	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact